- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077453
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Compare the effect of lower and intermittent doses of letrozole to standard letrozole therapy on estrogen suppression in postmenopausal women at high risk for developing breast cancer.
SECONDARY OBJECTIVES:
I. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on signs and symptoms of estrogen deficiency, including menopausal symptoms, serum lipid profile, and serum marker of bone turnover.
II. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on nuclear chromatin abnormality of breast epithelial cells collected by random periareolar fine needle aspiration (RPFNA).
TERTIARY OBJECTIVES:
I. Determine the prevalence of breast cancer stem cells in the fine needle breast aspirates and explore the potential intervention effect on the prevalence of breast cancer stem cells.
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
ARM I: Patients receive 2.5 mg of letrozole orally (PO) thrice weekly for 6 months.
ARM II: Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
ARM III: Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
ARM IV: Patients receive 2.5 mg of letrozole PO once daily for 6 months.
After completion of study treatment, patients are followed up at week 30.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona Health Sciences Center
-
Tucson, Arizona, United States, 85724-5024
- Arizona Cancer Center - Tucson
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy postmenopausal women at "high risk" for breast cancer will be eligible for the study; definition of menopause will be:
- Amenorrhea for at least 12 months, or
- History of hysterectomy and bilateral salpingo-oophorectomy, or
- At least 55 years of age with prior hysterectomy with or without oophorectomy, or
- Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range
"High risk" for breast cancer will be defined as:
- Prior histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only, or
- At least 1.66% probability of invasive breast cancer within 5 years using the Breast Cancer Risk Assessment Tool
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 80% or above
- Leukocytes >= 3,000/uL
- Absolute neutrophil count >= 1,500/uL
- Platelets >= 100,000/uL
- Total bilirubin =< 2.0 mg/dL
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 X institutional ULN
- Creatinine =< 1 X institutional ULN
- Recent mammogram negative for breast cancer, Breast Imaging-Reporting and Data System (BIRADS) score < 3 (within the last 12 months)
- Ability to understand and the willingness to sign a written informed consent document; only potential participants with the ability to understand and the willingness to sign a written document will be presented with an informed consenting document
Exclusion Criteria:
- Women diagnosed with osteoporosis (previously or on screening dual-energy X-ray absorptiometry [DEXA] for this study) and not on a stable dose of long or short-acting bisphosphonates therapy for at least 3 months will be excluded from the study; women diagnosed with osteoporosis and on raloxifene (Evista) therapy will be excluded from the study; use of calcium and/or vitamin D for osteoporosis prevention or treatment is allowed; women with osteopenia will be allowed to participate in this study
- Have had invasive cancer within the past five years except non-melanoma skin cancer
- Evidence of suspicious of malignant disease on bilateral mammogram within the past year unless ruled out by further evaluation
- History of prior invasive breast cancer or intraductal carcinoma in situ, or history of prior radiation therapy to the chest or breast
- Participants may not be receiving any other investigational agents; participants may not be concurrently enrolled in another breast cancer prevention intervention trial
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to letrozole
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Within 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens
- Within 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators
- Within 3 months since regular use (more than 2 times a week) of prior estrogenic supplements or herbal remedies
- History of bleeding or clotting disorder; current or recent (within 3 months) use of Coumadin, Plavix or other systemic anticoagulant other than aspirin is not permitted if subject chooses to participate in the optional RPFNA procedure; if a subject chooses not to participate in the RPFNA procedure, prior or current treatment with systemic anticoagulants is permitted
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (2.5 mg letrozole)
Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
|
Correlative studies
Ancillary studies
Other Names:
Given orally
Other Names:
|
Experimental: Arm II (1.0 mg letrozole)
Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
|
Correlative studies
Ancillary studies
Other Names:
Given orally
Other Names:
|
Experimental: Arm III (0.25 mg letrozole)
Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
|
Correlative studies
Ancillary studies
Other Names:
Given orally
Other Names:
|
Experimental: Arm IV (2.5 mg letrozole)
Patients receive 2.5 mg of letrozole PO once daily for 6 months.
|
Correlative studies
Ancillary studies
Other Names:
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of serum estradiol suppression in postmenopausal women at high risk for breast cancer
Time Frame: Baseline to week 30
|
Three one-sided two-sample t-tests will be conducted on the ratios of the mean percentage of suppression simultaneously to test for non-inferiority.
A multivariate t-distribution is used to derive the critical value and the power.
|
Baseline to week 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in serum estrone levels
Time Frame: Baseline to week 30
|
Three one-sided two-sample t-tests will be performed to evaluate the ratio of the mean changes (or percentage of changes) of each of the three intermittent dosing groups to that of the standard therapy control group simultaneously for each of the endpoints at an overall significance level of 5%.
|
Baseline to week 30
|
Change in serum testosterone levels
Time Frame: Baseline to week 30
|
Three one-sided two-sample t-tests will be performed to evaluate the ratio of the mean changes (or percentage of changes) of each of the three intermittent dosing groups to that of the standard therapy control group simultaneously for each of the endpoints at an overall significance level of 5%.
|
Baseline to week 30
|
Menopausal symptoms as assessed by quality of life measures, as assessed by Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Menopause Specific Quality of Life Questionnaire (MENQOL)
Time Frame: Up to week 30
|
Up to week 30
|
|
Nuclear chromatin abnormality as assessed by karyometry
Time Frame: Up to week 30
|
Up to week 30
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prevalence of breast cancer stem cells by the proportion of aldehyde dehydrogenase positive cells, assessed by the Aldeflour assay
Time Frame: Up to week 30
|
Up to week 30
|
Relative expression of stem cell markers to housekeeping genes, assessed by quantitative real time polymerase chain reaction
Time Frame: Up to week 30
|
Up to week 30
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ana Lopez, University of Arizona Health Sciences Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma in Situ
- Breast Neoplasms
- Breast Carcinoma In Situ
- Carcinoma, Lobular
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
Other Study ID Numbers
- NCI-2013-00757 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA023074 (U.S. NIH Grant/Contract)
- N01CN35158 (U.S. NIH Grant/Contract)
- 09-0869-04 (Other Identifier: University of Arizona Health Sciences Center)
- UAZ08-12-02 (Other Identifier: DCP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy, no Evidence of Disease
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
Cancer Research UKUnknownHealthy, no Evidence of DiseaseUnited Kingdom
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedHealthy, No Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)TerminatedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Completed
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States